Floatz logo

Cosibelimab

Renal Cell Carcinoma

Checkpoint Therapeutics, Inc.Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
65/ 100

Competitive context

297 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Cosibelimab is also rated in:

skin squamous cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →
skin cancerDormant
CCC
Indicative ·
54 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →